World News
-
Bristol Myers Squibb expands US manufacturing footprint with US$2.3B Houston facility
The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.
-
Jazz Pharmaceuticals to acquire Actio Biosciences in US$1.32B rare epilepsy deal
As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.
-
Abbott partners with Google Health to bring AI-powered metabolic health insights to consumers
The AI-powered guidance will focus on building sustainable habits related to diet, physical activity, recovery and sleep, helping individuals make informed lifestyle decisions in real time.
-
Eli Lilly wins UK MHRA approval for Foundayo weight-loss pill
The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) marks another milestone in the rapidly growing market for oral weight-loss medicines.
-
BeOne Medicines collaborates with Revolution Medicines on RAS-targeted cancer treatments
The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.
-
Philips expands connected patient monitoring ecosystem with six technology partnerships
The partnerships will enable healthcare providers to integrate wearable and out-of-hospital monitoring technologies into the Philips ecosystem.
-
Sobi strikes US$580M lacutamab deal with Innate Pharma for CTCL
The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.
-
Innovent Biologics to commercialise Daiichi Sankyo’s Vanflyta in China
Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.
-
Tarsus Pharmaceuticals to acquire Alkeus in US$800M deal to expand ophthalmology pipeline
The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.
-
Takeda secures FDA approval for oral orexin agonist Orzeyful in US market
The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.